2005
DOI: 10.1016/j.jcv.2004.10.004
|View full text |Cite
|
Sign up to set email alerts
|

Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
13
0
2

Year Published

2005
2005
2014
2014

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 16 publications
(16 citation statements)
references
References 19 publications
1
13
0
2
Order By: Relevance
“…7 In samples with an indeterminate Western blot pattern, a new blood sample was drawn and peripheral blood mononuclear cells were obtained to perform genetic confirmation by polymerase chain reaction (PCR) and phylogenetic analyses, using primers and conditions reported elsewhere. 8 Data from medical records were reviewed for subjects who were found to be HTLV seropositive.…”
Section: Methodsmentioning
confidence: 99%
“…7 In samples with an indeterminate Western blot pattern, a new blood sample was drawn and peripheral blood mononuclear cells were obtained to perform genetic confirmation by polymerase chain reaction (PCR) and phylogenetic analyses, using primers and conditions reported elsewhere. 8 Data from medical records were reviewed for subjects who were found to be HTLV seropositive.…”
Section: Methodsmentioning
confidence: 99%
“…HTLV-1 is more frequent among injection drug users in Brazil and New York [34][35][36][37][38] , whereas HTLV-2 is more prevalent in injection drug users in other locations in North America and in Europe [39][40][41][42][43][44] . In 2001, the fi rst cases of HTLV-1 transmission through organs that were transplanted from asymptomatic infected donors were reported in Europe; three donor organ recipients developed subacute myelopathy shortly after transplantation 45 .…”
Section: Modes Of Htlv Transmissionmentioning
confidence: 99%
“…In addition, HTLV-2 infection has been associated with sporadic cases of a myelopathy resembling HAM/TSP (Hjelle et al, 1992;Dooneief et al, 1996;Murphy et al, 1997), but has not been clearly linked with the development of lymphoproliferative disorders. HTLV-2 infection is highly concentrated in Central and West Africa (Gessain et al, 1993;Goubau et al, 1993), native Amerindian populations in North, Central, and South America (Hjelle et al, 1990;Lairmore et al, 1990;Heneine et al, 1991;Levine et al, 1993), and among cohorts of intravenous drug users (IVDUs) in the United States and Europe (Tedder et al, 1984;Robert-Guroff et al, 1986;Lee et al, 1989;Khabbaz et al, 1991;Toro et al, 2005).…”
Section: Introductionmentioning
confidence: 99%